Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 191 entries
Sorted by: Best Match Show Resources per page
Corrigendum to "Acid-labile pHPMA modification of four-arm oligoaminoamide pDNA polyplexes balances shielding and gene transfer activity in vitro and in vivo" [Euro. J. Pharm. Biopharm. 105 (2016) 85-96].

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Beckert L, Kostka L, Kessel E, Krhac Levacic A, Kostkova H, Etrych T, Lächelt U, Wagner E.
PMID: 28130965
Eur J Pharm Biopharm. 2017 Apr;113:240. doi: 10.1016/j.ejpb.2017.01.010. Epub 2017 Jan 26.

No abstract available.

Cite
Beckert L, Kostka L, Kessel E, et al. Corrigendum to "Acid-labile pHPMA modification of four-arm oligoaminoamide pDNA polyplexes balances shielding and gene transfer activity in vitro and in vivo" [Euro. J. Pharm. Biopharm. 105 (2016) 85-96]. Eur J Pharm Biopharm. 2017;113:240doi: 10.1016/j.ejpb.2017.01.010.
Beckert, L., Kostka, L., Kessel, E., Krhac Levacic, A., Kostkova, H., Etrych, T., Lächelt, U., & Wagner, E. (2017). Corrigendum to "Acid-labile pHPMA modification of four-arm oligoaminoamide pDNA polyplexes balances shielding and gene transfer activity in vitro and in vivo" [Euro. J. Pharm. Biopharm. 105 (2016) 85-96]. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 113240. https://doi.org/10.1016/j.ejpb.2017.01.010
Beckert, Linda, et al. "Corrigendum to "Acid-labile pHPMA modification of four-arm oligoaminoamide pDNA polyplexes balances shielding and gene transfer activity in vitro and in vivo" [Euro. J. Pharm. Biopharm. 105 (2016) 85-96]." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. 113 (2017): 240. doi: https://doi.org/10.1016/j.ejpb.2017.01.010
Beckert L, Kostka L, Kessel E, Krhac Levacic A, Kostkova H, Etrych T, Lächelt U, Wagner E. Corrigendum to "Acid-labile pHPMA modification of four-arm oligoaminoamide pDNA polyplexes balances shielding and gene transfer activity in vitro and in vivo" [Euro. J. Pharm. Biopharm. 105 (2016) 85-96]. Eur J Pharm Biopharm. 2017 Apr;113:240. doi: 10.1016/j.ejpb.2017.01.010. Epub 2017 Jan 26. PMID: 28130965.
Copy Download .nbib Format: NLM
Corrigendum to "The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model." [Eur. J. Pharm. Biopharm. 94 (2015) 521-531].

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Alibolandi M, Sadeghi F, Abnous K, Atyabi F, Ramezani M, Hadizadeh F.
PMID: 31470967
Eur J Pharm Biopharm. 2019 Sep;142:540. doi: 10.1016/j.ejpb.2019.02.005. Epub 2019 Aug 08.

No abstract available.

Cite
Alibolandi M, Sadeghi F, Abnous K, et al. Corrigendum to "The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model." [Eur. J. Pharm. Biopharm. 94 (2015) 521-531]. Eur J Pharm Biopharm. 2019;142:540doi: 10.1016/j.ejpb.2019.02.005.
Alibolandi, M., Sadeghi, F., Abnous, K., Atyabi, F., Ramezani, M., & Hadizadeh, F. (2019). Corrigendum to "The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model." [Eur. J. Pharm. Biopharm. 94 (2015) 521-531]. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 142540. https://doi.org/10.1016/j.ejpb.2019.02.005
Alibolandi, Mona, et al. "Corrigendum to "The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model." [Eur. J. Pharm. Biopharm. 94 (2015) 521-531]." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. 142 (2019): 540. doi: https://doi.org/10.1016/j.ejpb.2019.02.005
Alibolandi M, Sadeghi F, Abnous K, Atyabi F, Ramezani M, Hadizadeh F. Corrigendum to "The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model." [Eur. J. Pharm. Biopharm. 94 (2015) 521-531]. Eur J Pharm Biopharm. 2019 Sep;142:540. doi: 10.1016/j.ejpb.2019.02.005. Epub 2019 Aug 08. PMID: 31470967.
Copy Download .nbib Format: NLM
Corrigendum to "Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection" [Eur. J. Pharm. Biopharm. 111 (2017) 33-43].

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Tan Z, Liu W, Liu H, Li C, Zhang Y, Meng X, Tang T, Xi T, Xing Y.
PMID: 31735275
Eur J Pharm Biopharm. 2019 Dec;145:96-97. doi: 10.1016/j.ejpb.2019.10.006. Epub 2019 Nov 07.

No abstract available.

Cite
Tan Z, Liu W, Liu H, et al. Corrigendum to "Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection" [Eur. J. Pharm. Biopharm. 111 (2017) 33-43]. Eur J Pharm Biopharm. 2019;145:96-97doi: 10.1016/j.ejpb.2019.10.006.
Tan, Z., Liu, W., Liu, H., Li, C., Zhang, Y., Meng, X., Tang, T., Xi, T., & Xing, Y. (2019). Corrigendum to "Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection" [Eur. J. Pharm. Biopharm. 111 (2017) 33-43]. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 14596-97. https://doi.org/10.1016/j.ejpb.2019.10.006
Tan, Zhoulin, et al. "Corrigendum to "Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection" [Eur. J. Pharm. Biopharm. 111 (2017) 33-43]." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. 145 (2019): 96-97. doi: https://doi.org/10.1016/j.ejpb.2019.10.006
Tan Z, Liu W, Liu H, Li C, Zhang Y, Meng X, Tang T, Xi T, Xing Y. Corrigendum to "Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection" [Eur. J. Pharm. Biopharm. 111 (2017) 33-43]. Eur J Pharm Biopharm. 2019 Dec;145:96-97. doi: 10.1016/j.ejpb.2019.10.006. Epub 2019 Nov 07. PMID: 31735275.
Copy Download .nbib Format: NLM
In vitro - in vivo relations for the parenteral liposomal formulation of Amphotericin B: A clinically relevant approach with PBPK modeling.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Díaz de León-Ortega R, D'Arcy DM, Lamprou DA, Fotaki N.
PMID: 32147578
Eur J Pharm Biopharm. 2020 Mar 05;177-187. doi: 10.1016/j.ejpb.2020.03.001. Epub 2020 Mar 05.

In vitro release testing is a useful tool for the quality control of controlled release parenteral formulations, but in vitro release test conditions that reflect or are able to predict the in vivo performance are advantageous. Therefore, it is...

Cite
Díaz de León-Ortega R, D'Arcy DM, Lamprou DA, et al. In vitro - in vivo relations for the parenteral liposomal formulation of Amphotericin B: A clinically relevant approach with PBPK modeling. Eur J Pharm Biopharm. 2020;177-187doi: 10.1016/j.ejpb.2020.03.001.
Díaz de León-Ortega, R., D'Arcy, D. M., Lamprou, D. A., & Fotaki, N. (2020). In vitro - in vivo relations for the parenteral liposomal formulation of Amphotericin B: A clinically relevant approach with PBPK modeling. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 177-187. https://doi.org/10.1016/j.ejpb.2020.03.001
Díaz de León-Ortega, R, et al. "In vitro - in vivo relations for the parenteral liposomal formulation of Amphotericin B: A clinically relevant approach with PBPK modeling." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. (2020): 177-187. doi: https://doi.org/10.1016/j.ejpb.2020.03.001
Díaz de León-Ortega R, D'Arcy DM, Lamprou DA, Fotaki N. In vitro - in vivo relations for the parenteral liposomal formulation of Amphotericin B: A clinically relevant approach with PBPK modeling. Eur J Pharm Biopharm. 2020 Mar 05;177-187. doi: 10.1016/j.ejpb.2020.03.001. Epub 2020 Mar 05. PMID: 32147578.
Copy Download .nbib Format: NLM
Lecithin-based nanoemulsions of traditional herbal wound healing agents and their effect on human skin cells.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Vater C, Bosch L, Mitter A, Göls T, Seiser S, Heiss E, Elbe-Bürger A, Wirth M, Valenta C, Klang V.
PMID: 34798283
Eur J Pharm Biopharm. 2021 Nov 16; doi: 10.1016/j.ejpb.2021.11.004. Epub 2021 Nov 16.

In previous studies, lecithin-based nanoemulsions (NEs) have been shown to be skin friendly drug carrier systems. Due to their nontoxic properties, NEs might also be suitable as wound healing agents. Hence, different O/W NEs based on lecithin Lipoid® S...

Cite
Vater C, Bosch L, Mitter A, et al. Lecithin-based nanoemulsions of traditional herbal wound healing agents and their effect on human skin cells. Eur J Pharm Biopharm. 2021;doi: 10.1016/j.ejpb.2021.11.004.
Vater, C., Bosch, L., Mitter, A., Göls, T., Seiser, S., Heiss, E., Elbe-Bürger, A., Wirth, M., Valenta, C., & Klang, V. (2021). Lecithin-based nanoemulsions of traditional herbal wound healing agents and their effect on human skin cells. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, . https://doi.org/10.1016/j.ejpb.2021.11.004
Vater, Claudia, et al. "Lecithin-based nanoemulsions of traditional herbal wound healing agents and their effect on human skin cells." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. (2021). doi: https://doi.org/10.1016/j.ejpb.2021.11.004
Vater C, Bosch L, Mitter A, Göls T, Seiser S, Heiss E, Elbe-Bürger A, Wirth M, Valenta C, Klang V. Lecithin-based nanoemulsions of traditional herbal wound healing agents and their effect on human skin cells. Eur J Pharm Biopharm. 2021 Nov 16; doi: 10.1016/j.ejpb.2021.11.004. Epub 2021 Nov 16. PMID: 34798283.
Copy Download .nbib Format: NLM
Optimized molecular imprints in gamma-irradiated collagen shields of an antifungal drug: In vitro characterization, in-vivo bioavailability enhancement.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Abouelatta SM, Sheta AI, Ibrahim RR.
PMID: 34166761
Eur J Pharm Biopharm. 2021 Sep;166:135-143. doi: 10.1016/j.ejpb.2021.06.008. Epub 2021 Jun 21.

The purpose of this manuscript is to develop sustained release molecularly imprinted voriconazole (VOR) that were loaded into collagen shield (CS) for ocular treatment of fungal keratitis. Various molecularly imprinted polymer (MIP) formulae were prepared by a precipitation polymerization...

Cite
Abouelatta SM, Sheta AI, Ibrahim RR. Optimized molecular imprints in gamma-irradiated collagen shields of an antifungal drug: In vitro characterization, in-vivo bioavailability enhancement. Eur J Pharm Biopharm. 2021;166:135-143doi: 10.1016/j.ejpb.2021.06.008.
Abouelatta, S. M., Sheta, A. I., & Ibrahim, R. R. (2021). Optimized molecular imprints in gamma-irradiated collagen shields of an antifungal drug: In vitro characterization, in-vivo bioavailability enhancement. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 166135-143. https://doi.org/10.1016/j.ejpb.2021.06.008
Abouelatta, Samar M, et al. "Optimized molecular imprints in gamma-irradiated collagen shields of an antifungal drug: In vitro characterization, in-vivo bioavailability enhancement." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. 166 (2021): 135-143. doi: https://doi.org/10.1016/j.ejpb.2021.06.008
Abouelatta SM, Sheta AI, Ibrahim RR. Optimized molecular imprints in gamma-irradiated collagen shields of an antifungal drug: In vitro characterization, in-vivo bioavailability enhancement. Eur J Pharm Biopharm. 2021 Sep;166:135-143. doi: 10.1016/j.ejpb.2021.06.008. Epub 2021 Jun 21. PMID: 34166761.
Copy Download .nbib Format: NLM
Mesalazine and inflammatory bowel disease - From well-established therapies to progress beyond the state of the art.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Veloso PM, Machado R, Nobre C.
PMID: 34329709
Eur J Pharm Biopharm. 2021 Oct;167:89-103. doi: 10.1016/j.ejpb.2021.07.014. Epub 2021 Jul 28.

Inflammatory bowel disease incidence has been constantly rising for the past few decades. Current therapies attempt to mitigate its symptoms since no cure is established. The most commonly prescribed drug for these patients is 5-aminosalicylic acid (5-ASA). Due to...

Cite
Veloso PM, Machado R, Nobre C. Mesalazine and inflammatory bowel disease - From well-established therapies to progress beyond the state of the art. Eur J Pharm Biopharm. 2021;167:89-103doi: 10.1016/j.ejpb.2021.07.014.
Veloso, P. M., Machado, R., & Nobre, C. (2021). Mesalazine and inflammatory bowel disease - From well-established therapies to progress beyond the state of the art. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 16789-103. https://doi.org/10.1016/j.ejpb.2021.07.014
Veloso, Pedro M, et al. "Mesalazine and inflammatory bowel disease - From well-established therapies to progress beyond the state of the art." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. 167 (2021): 89-103. doi: https://doi.org/10.1016/j.ejpb.2021.07.014
Veloso PM, Machado R, Nobre C. Mesalazine and inflammatory bowel disease - From well-established therapies to progress beyond the state of the art. Eur J Pharm Biopharm. 2021 Oct;167:89-103. doi: 10.1016/j.ejpb.2021.07.014. Epub 2021 Jul 28. PMID: 34329709.
Copy Download .nbib Format: NLM
Osteosarcoma from the unknown to the use of exosomes as a versatile and dynamic therapeutic approach.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Santos A, Domingues C, Jarak I, Veiga F, Figueiras A.
PMID: 34896571
Eur J Pharm Biopharm. 2022 Jan;170:91-111. doi: 10.1016/j.ejpb.2021.12.003. Epub 2021 Dec 10.

The most common primary malignant tumor of bone in children is osteosarcoma (OS). Nowadays, the prognosis and the introduction of chemotherapy in OS have improved survival rates of patients. Nevertheless, the results are still unsatisfactory, especially, in patients with...

Cite
Santos A, Domingues C, Jarak I, et al. Osteosarcoma from the unknown to the use of exosomes as a versatile and dynamic therapeutic approach. Eur J Pharm Biopharm. 2021;170:91-111doi: 10.1016/j.ejpb.2021.12.003.
Santos, A., Domingues, C., Jarak, I., Veiga, F., & Figueiras, A. (2022). Osteosarcoma from the unknown to the use of exosomes as a versatile and dynamic therapeutic approach. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 17091-111. https://doi.org/10.1016/j.ejpb.2021.12.003
Santos, Ana, et al. "Osteosarcoma from the unknown to the use of exosomes as a versatile and dynamic therapeutic approach." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. 170 (2022): 91-111. doi: https://doi.org/10.1016/j.ejpb.2021.12.003
Santos A, Domingues C, Jarak I, Veiga F, Figueiras A. Osteosarcoma from the unknown to the use of exosomes as a versatile and dynamic therapeutic approach. Eur J Pharm Biopharm. 2022 Jan;170:91-111. doi: 10.1016/j.ejpb.2021.12.003. Epub 2021 Dec 10. PMID: 34896571.
Copy Download .nbib Format: NLM
Quantifying the heterogeneity of enzymatic dePEGyaltion of liposomal nanocarrier systems.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Eliasen R, Lars Andresen T, Bruun Larsen J.
PMID: 35021105
Eur J Pharm Biopharm. 2022 Jan 09; doi: 10.1016/j.ejpb.2021.12.013. Epub 2022 Jan 09.

Lipid nanoparticles have been clinically successful in particular recently within the vaccine field, but better tools are needed to analyze heterogeneities at the single particle level to progress drug delivery designs to the next level. Especially, liposomal nanocarriers are...

Cite
Eliasen R, Lars Andresen T, Bruun Larsen J. Quantifying the heterogeneity of enzymatic dePEGyaltion of liposomal nanocarrier systems. Eur J Pharm Biopharm. 2022;doi: 10.1016/j.ejpb.2021.12.013.
Eliasen, R., Lars Andresen, T., & Bruun Larsen, J. (2022). Quantifying the heterogeneity of enzymatic dePEGyaltion of liposomal nanocarrier systems. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, . https://doi.org/10.1016/j.ejpb.2021.12.013
Eliasen, Rasmus, et al. "Quantifying the heterogeneity of enzymatic dePEGyaltion of liposomal nanocarrier systems." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. (2022). doi: https://doi.org/10.1016/j.ejpb.2021.12.013
Eliasen R, Lars Andresen T, Bruun Larsen J. Quantifying the heterogeneity of enzymatic dePEGyaltion of liposomal nanocarrier systems. Eur J Pharm Biopharm. 2022 Jan 09; doi: 10.1016/j.ejpb.2021.12.013. Epub 2022 Jan 09. PMID: 35021105.
Copy Download .nbib Format: NLM
Design, fabrication, and characterisation of a silicon microneedle array for transdermal therapeutic delivery using a single step wet etch process.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Howells O, Blayney GJ, Gualeni B, Birchall JC, Eng PF, Ashraf H, Sharma S, Guy OJ.
PMID: 34144128
Eur J Pharm Biopharm. 2021 Jun 15; doi: 10.1016/j.ejpb.2021.06.005. Epub 2021 Jun 15.

The fabrication of silicon in-plane microneedle arrays from a simple single wet etch step is presented. The characteristic 54.7° sidewall etch angle obtained via KOH etching of (100) orientation silicon wafers has been used to create a novel microneedle...

Cite
Howells O, Blayney GJ, Gualeni B, et al. Design, fabrication, and characterisation of a silicon microneedle array for transdermal therapeutic delivery using a single step wet etch process. Eur J Pharm Biopharm. 2021;doi: 10.1016/j.ejpb.2021.06.005.
Howells, O., Blayney, G. J., Gualeni, B., Birchall, J. C., Eng, P. F., Ashraf, H., Sharma, S., & Guy, O. J. (2021). Design, fabrication, and characterisation of a silicon microneedle array for transdermal therapeutic delivery using a single step wet etch process. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, . https://doi.org/10.1016/j.ejpb.2021.06.005
Howells, Olivia, et al. "Design, fabrication, and characterisation of a silicon microneedle array for transdermal therapeutic delivery using a single step wet etch process." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. (2021). doi: https://doi.org/10.1016/j.ejpb.2021.06.005
Howells O, Blayney GJ, Gualeni B, Birchall JC, Eng PF, Ashraf H, Sharma S, Guy OJ. Design, fabrication, and characterisation of a silicon microneedle array for transdermal therapeutic delivery using a single step wet etch process. Eur J Pharm Biopharm. 2021 Jun 15; doi: 10.1016/j.ejpb.2021.06.005. Epub 2021 Jun 15. PMID: 34144128.
Copy Download .nbib Format: NLM
Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Li Z, Perkins W, Cipolla D.
PMID: 34082122
Eur J Pharm Biopharm. 2021 Sep;166:10-18. doi: 10.1016/j.ejpb.2021.05.021. Epub 2021 Jun 01.

The purpose of these studies was to understand the effect on product performance of batch-to-batch variability in both the amikacin liposome inhalation suspension (ALIS) formulation and its delivery device, the Lamira® nebulizer system, designed and manufactured by PARI (PARI...

Cite
Li Z, Perkins W, Cipolla D. Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology. Eur J Pharm Biopharm. 2021;166:10-18doi: 10.1016/j.ejpb.2021.05.021.
Li, Z., Perkins, W., & Cipolla, D. (2021). Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 16610-18. https://doi.org/10.1016/j.ejpb.2021.05.021
Li, Zhili, et al. "Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. 166 (2021): 10-18. doi: https://doi.org/10.1016/j.ejpb.2021.05.021
Li Z, Perkins W, Cipolla D. Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology. Eur J Pharm Biopharm. 2021 Sep;166:10-18. doi: 10.1016/j.ejpb.2021.05.021. Epub 2021 Jun 01. PMID: 34082122.
Copy Download .nbib Format: NLM
Intestinal permeation enhancers enable oral delivery of macromolecules up to 70 kDa in size.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Fein KC, Gleeson JP, Newby AN, Whitehead KA.
PMID: 34879228
Eur J Pharm Biopharm. 2022 Jan;170:70-76. doi: 10.1016/j.ejpb.2021.11.010. Epub 2021 Dec 05.

The decades-long effort to deliver peptide drugs orally has resulted in several clinically successful formulations. These formulations are enabled by the inclusion of permeation enhancers that facilitate the intestinal absorption of peptides. Thus far, these oral peptide drugs have...

Cite
Fein KC, Gleeson JP, Newby AN, et al. Intestinal permeation enhancers enable oral delivery of macromolecules up to 70 kDa in size. Eur J Pharm Biopharm. 2021;170:70-76doi: 10.1016/j.ejpb.2021.11.010.
Fein, K. C., Gleeson, J. P., Newby, A. N., & Whitehead, K. A. (2022). Intestinal permeation enhancers enable oral delivery of macromolecules up to 70 kDa in size. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 17070-76. https://doi.org/10.1016/j.ejpb.2021.11.010
Fein, Katherine C, et al. "Intestinal permeation enhancers enable oral delivery of macromolecules up to 70 kDa in size." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. 170 (2022): 70-76. doi: https://doi.org/10.1016/j.ejpb.2021.11.010
Fein KC, Gleeson JP, Newby AN, Whitehead KA. Intestinal permeation enhancers enable oral delivery of macromolecules up to 70 kDa in size. Eur J Pharm Biopharm. 2022 Jan;170:70-76. doi: 10.1016/j.ejpb.2021.11.010. Epub 2021 Dec 05. PMID: 34879228.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 191 entries